Cited 6 times in
Ramucirumab plus paclitaxel as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma: a nationwide real-world outcomes in Korea study (KCSG-ST19-16)
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 라선영 | - |
dc.date.accessioned | 2022-09-14T01:34:38Z | - |
dc.date.available | 2022-09-14T01:34:38Z | - |
dc.date.issued | 2021-09 | - |
dc.identifier.issn | 1758-8340 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/190527 | - |
dc.description.abstract | Background: Ramucirumab as monotherapy or in combination with paclitaxel is a second-line treatment option recommended for patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma. However, real-world data from large study cohorts focused on ramucirumab plus paclitaxel in gastric cancer are limited. Methods: The study population comprised all patients with gastric or GEJ cancer who received ramucirumab plus paclitaxel in South Korea between 1 May 2018 and 31 December 2018. We included patients with advanced gastric or GEJ adenocarcinoma and disease progression after first-line platinum and fluoropyrimidine-containing combination chemotherapy. Results: In total, 1063 patients were included in the present study. The objective response rate and disease control rate were 15.1% and 57.7%, respectively. The median progression-free survival was 4.03 months (95% confidence interval, 3.80-4.27) and the median overall survival was 10.03 months (95% confidence interval, 9.33-10.73). Grade 3 or higher treatment-related adverse events with incidence of ⩾5% were neutropenia (35.1%) and anemia (10.5%). Based on multivariable analysis, overall survival was negatively associated with Eastern Cooperative Oncology Group performance status ⩾2, weight loss ⩾10% in the previous 3 months, GEJ of primary tumor, poor or unknown histologic grade, number of metastatic sites ⩾3, presence of peritoneal metastasis, no prior gastrectomy, and time to second-line since first-line treatment <6 months. Conclusion: Our large-scale, nationwide, real-world data analysis of an unselected real-world population adds evidence for the efficacy and safety of second-line ramucirumab plus paclitaxel in patients with locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Sage | - |
dc.relation.isPartOf | THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Ramucirumab plus paclitaxel as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma: a nationwide real-world outcomes in Korea study (KCSG-ST19-16) | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Hye Sook Han | - |
dc.contributor.googleauthor | Bum Jun Kim | - |
dc.contributor.googleauthor | Hee-Jung Jee | - |
dc.contributor.googleauthor | Min-Hee Ryu | - |
dc.contributor.googleauthor | Se Hoon Park | - |
dc.contributor.googleauthor | Sun Young Rha | - |
dc.contributor.googleauthor | Jong Gwang Kim | - |
dc.contributor.googleauthor | Woo Kyun Bae | - |
dc.contributor.googleauthor | Keun-Wook Lee | - |
dc.contributor.googleauthor | Do-Youn Oh | - |
dc.contributor.googleauthor | In-Ho Kim | - |
dc.contributor.googleauthor | Sun Jin Sym | - |
dc.contributor.googleauthor | So Yeon Oh | - |
dc.contributor.googleauthor | Hyeong Su Kim | - |
dc.contributor.googleauthor | Ji-Hye Byun | - |
dc.contributor.googleauthor | Dong Sook Kim | - |
dc.contributor.googleauthor | Young Ju Suh | - |
dc.contributor.googleauthor | Hyonggin An | - |
dc.contributor.googleauthor | Dae Young Zang | - |
dc.identifier.doi | 10.1177/17588359211042812 | - |
dc.contributor.localId | A01316 | - |
dc.relation.journalcode | J02720 | - |
dc.identifier.eissn | 1758-8359 | - |
dc.identifier.pmid | 34552667 | - |
dc.subject.keyword | gastric cancer | - |
dc.subject.keyword | paclitaxel | - |
dc.subject.keyword | ramucirumab | - |
dc.subject.keyword | real-world data | - |
dc.contributor.alternativeName | Rha, Sun Young | - |
dc.contributor.affiliatedAuthor | 라선영 | - |
dc.citation.volume | 13 | - |
dc.citation.startPage | 17588359211042812 | - |
dc.identifier.bibliographicCitation | THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, Vol.13 : 17588359211042812, 2021-09 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.